Pharmaceuticals, Biotechnology and Life Sciences
EMERYVILLE, Calif.–(BUSINESS WIRE)–Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T cell therapies to treat solid tumors, today…
– Meeting on ITI-1001 Phase I program for treatment of Newly-Diagnosed Glioblastoma (GBM) ROCKVILLE, Md.–(BUSINESS WIRE)–Immunomic Therapeutics, Inc., a privately…
REHOVOT, Israel & WILMINGTON, Del.–(BUSINESS WIRE)–Ayala Pharmaceuticals, Inc., a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics…
REHOVOT, Israel & WILMINGTON, Del.–(BUSINESS WIRE)–Ayala Pharmaceuticals, Inc., a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics…
BEDFORD, Mass.–(BUSINESS WIRE)–$OCUL #OCUTX–Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative…
– Friedreich’s ataxia chosen as first neurological indication – Reported Phase 1b data for lead immuno-oncology candidate in solid tumors…
– Friedreich’s ataxia chosen as first neurological indication – Reported Phase 1b data for lead immuno-oncology candidate in solid tumors…
Novel Mechanism of Action Inhibits Pathological Activation of Microglial Cells and Prevents Neuronal Cell Death GERMANTOWN, Md.–(BUSINESS WIRE)–Neuraly, a clinical…
Novel Mechanism of Action Inhibits Pathological Activation of Microglial Cells and Prevents Neuronal Cell Death GERMANTOWN, Md.–(BUSINESS WIRE)–Neuraly, a clinical…
− GIVLAARI is the First and Only Therapy Proven to Prevent AHP Attacks, Reduce Chronic Pain and Improve Quality of…